Durivage HJ - Search Results

1

A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix.

Irvin WP, Price FV, Bailey H, Gelder M, Rosenbluth R, Durivage HJ, Potkul RK. Irvin WP, et al. Among authors: durivage hj. Cancer. 1998 Jan 15;82(2):328-33. doi: 10.1002/(sici)1097-0142(19980115)82:2<334::aid-cncr13>3.0.co;2-#. Cancer. 1998. PMID: 9445190 Clinical Trial.

2

High-dose cisplatin with dacarbazine and tamoxifen in the treatment of metastatic melanoma.

Buzaid AC, Murren JR, Durivage HJ. Buzaid AC, et al. Among authors: durivage hj. Cancer. 1991 Sep 15;68(6):1238-41. doi: 10.1002/1097-0142(19910915)68:6<1238::aid-cncr2820680609>3.0.co;2-#. Cancer. 1991. PMID: 1873775 Clinical Trial.

3

High-dose cisplatin plus dacarbazine in the treatment of metastatic melanoma.

Murren JR, DeRosa W, Durivage HJ, Davis C, Makuch R, Portlock CS. Murren JR, et al. Among authors: durivage hj. Cancer. 1991 Mar 15;67(6):1514-7. doi: 10.1002/1097-0142(19910315)67:6<1514::aid-cncr2820670609>3.0.co;2-q. Cancer. 1991. PMID: 2001539 Clinical Trial.

4

A phase I pilot study of BCNU plus thymidine in patients with refractory cancer.

Schultz MZ, Sandler AB, Durivage HJ, Cooper DL. Schultz MZ, et al. Among authors: durivage hj. Cancer Invest. 1996;14(3):218-24. doi: 10.3109/07357909609012142. Cancer Invest. 1996. PMID: 8630682 Clinical Trial.

5

Cyclosporine treatment of refractory T-cell lymphomas.

Cooper DL, Braverman IM, Sarris AH, Durivage HJ, Saidman BH, Davis CA, Hait WN. Cooper DL, et al. Among authors: durivage hj. Cancer. 1993 Apr 1;71(7):2335-41. doi: 10.1002/1097-0142(19930401)71:7<2335::aid-cncr2820710727>3.0.co;2-d. Cancer. 1993. PMID: 8453556 Clinical Trial.

6

Phase I trial of combined therapy with bleomycin and the calmodulin antagonist, trifluoperazine.

Hait WN, Morris S, Lazo JS, Figlin RJ, Durivage HJ, White K, Schwartz PE. Hait WN, et al. Among authors: durivage hj. Cancer Chemother Pharmacol. 1989;23(6):358-62. doi: 10.1007/BF00435836. Cancer Chemother Pharmacol. 1989. PMID: 2469543

7

Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial.

Chung V, Mansfield AS, Braiteh F, Richards D, Durivage H, Ungerleider RS, Johnson F, Kovach JS. Chung V, et al. Clin Cancer Res. 2017 Jul 1;23(13):3277-3284. doi: 10.1158/1078-0432.CCR-16-2299. Epub 2016 Dec 30. Clin Cancer Res. 2017. PMID: 28039265

8

High-dose cisplatin plus WR-2721 in a split course in metastatic malignant melanoma. A phase II study.

Buzaid AC, Murren J, Durivage HJ. Buzaid AC, et al. Among authors: durivage hj. Am J Clin Oncol. 1991 Jun;14(3):203-7. Am J Clin Oncol. 1991. PMID: 1851602 Clinical Trial.

9

The effect of calmodulin inhibitors with bleomycin on the treatment of patients with high grade gliomas.

Hait WN, Byrne TN, Piepmeier J, Durivage HJ, Choudhury S, Davis CA, Gates JA. Hait WN, et al. Among authors: durivage hj. Cancer Res. 1990 Oct 15;50(20):6636-40. Cancer Res. 1990. PMID: 1698540 Clinical Trial.

10

Trifluoperazine as a modulator of multidrug resistance in refractory breast cancer.

Murren JR, Durivage HJ, Buzaid AC, Reiss M, Flynn SD, Carter D, Hait WN. Murren JR, et al. Among authors: durivage hj. Cancer Chemother Pharmacol. 1996;38(1):65-70. doi: 10.1007/s002800050449. Cancer Chemother Pharmacol. 1996. PMID: 8603454 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

18 results

Search Page

Filters